prednisolone has been researched along with Coronary Artery Disease in 11 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day) or intravenous immunoglobulin plus prednisolone (the same intravenous immunoglobulin regimen as the intravenous immunoglobulin group plus prednisolone 2 mg/kg per day given over 15 days after concentrations of C-reactive protein normalised)." | 9.16 | Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. ( Arakawa, H; Fukazawa, R; Furuno, K; Fuse, S; Hamaoka, K; Hara, S; Hara, T; Ichida, F; Kato, T; Kobayashi, T; Miura, M; Morikawa, A; Nakamura, T; Nomura, Y; Ogawa, C; Ogawa, S; Otani, T; Saji, T; Seki, M; Takatsuki, S; Takeuchi, K; Tokunaga, H, 2012) |
| "We reported previously that intravenous immunoglobulin (IVIG) plus prednisolone for initial therapy for Kawasaki disease (KD) prevented coronary artery abnormalities (CAA) more effectively than IVIG alone." | 7.75 | Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. ( Arakawa, H; Inoue, Y; Kobayashi, T; Miura, M; Morikawa, A; Ogawa, S; Otani, T; Saji, T; Sonobe, T; Takeuchi, K, 2009) |
| " Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day) or intravenous immunoglobulin plus prednisolone (the same intravenous immunoglobulin regimen as the intravenous immunoglobulin group plus prednisolone 2 mg/kg per day given over 15 days after concentrations of C-reactive protein normalised)." | 5.16 | Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. ( Arakawa, H; Fukazawa, R; Furuno, K; Fuse, S; Hamaoka, K; Hara, S; Hara, T; Ichida, F; Kato, T; Kobayashi, T; Miura, M; Morikawa, A; Nakamura, T; Nomura, Y; Ogawa, C; Ogawa, S; Otani, T; Saji, T; Seki, M; Takatsuki, S; Takeuchi, K; Tokunaga, H, 2012) |
| "We reported previously that intravenous immunoglobulin (IVIG) plus prednisolone for initial therapy for Kawasaki disease (KD) prevented coronary artery abnormalities (CAA) more effectively than IVIG alone." | 3.75 | Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. ( Arakawa, H; Inoue, Y; Kobayashi, T; Miura, M; Morikawa, A; Ogawa, S; Otani, T; Saji, T; Sonobe, T; Takeuchi, K, 2009) |
| "The cause was established to be metal allergy, as determined by patch tests which were strongly positive for bare metal stents and weakly positive for CoCr-EES." | 1.43 | Metal allergy to everolimus-eluting cobalt chromium stents confirmed by positive skin testing as a cause of recurrent multivessel in-stent restenosis. ( Itoh, T; Morino, Y; Nakajima, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okubo, Y | 1 |
| Michihata, N | 1 |
| Morisaki, N | 1 |
| Sundel, RP | 1 |
| Matsui, H | 1 |
| Fushimi, K | 1 |
| Yasunaga, H | 1 |
| Matsuda, J | 1 |
| Takano, H | 1 |
| Shimizu, W | 1 |
| Etoom, Y | 1 |
| Banihani, R | 1 |
| Finkelstein, Y | 1 |
| Nakajima, Y | 1 |
| Itoh, T | 1 |
| Morino, Y | 1 |
| Wardle, AJ | 1 |
| Connolly, GM | 1 |
| Seager, MJ | 1 |
| Tulloh, RM | 1 |
| Kobayashi, T | 3 |
| Inoue, Y | 1 |
| Otani, T | 2 |
| Morikawa, A | 2 |
| Takeuchi, K | 2 |
| Saji, T | 2 |
| Sonobe, T | 1 |
| Ogawa, S | 2 |
| Miura, M | 2 |
| Arakawa, H | 2 |
| Fatimi, S | 1 |
| Kella, DK | 1 |
| Muzaffar, M | 1 |
| Hanif, HM | 1 |
| Ikutomi, M | 1 |
| Matsumura, T | 1 |
| Iwata, H | 1 |
| Nishimura, G | 1 |
| Ishizaka, N | 1 |
| Hirata, Y | 1 |
| Ono, M | 1 |
| Nagai, R | 1 |
| Son, MB | 1 |
| Newburger, JW | 1 |
| Nakamura, T | 1 |
| Kato, T | 1 |
| Hara, T | 1 |
| Hamaoka, K | 1 |
| Nomura, Y | 1 |
| Fuse, S | 1 |
| Ichida, F | 1 |
| Seki, M | 1 |
| Fukazawa, R | 1 |
| Ogawa, C | 1 |
| Furuno, K | 1 |
| Tokunaga, H | 1 |
| Takatsuki, S | 1 |
| Hara, S | 1 |
| Miyachi, H | 1 |
| Tanaka, K | 1 |
| Mizuno, K | 1 |
1 review available for prednisolone and Coronary Artery Disease
| Article | Year |
|---|---|
Corticosteroids for the treatment of Kawasaki disease in children.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Coronary Artery Disease | 2017 |
1 trial available for prednisolone and Coronary Artery Disease
| Article | Year |
|---|---|
Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Topics: Anti-Inflammatory Agents; Aspirin; Child, Preschool; Coronary Artery Disease; Coronary Vessel Anomal | 2012 |
9 other studies available for prednisolone and Coronary Artery Disease
| Article | Year |
|---|---|
Association Between Dose of Glucocorticoids and Coronary Artery Lesions in Kawasaki Disease.
Topics: Child, Preschool; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Glucocorticoids | 2018 |
IgG4-related periarteritis in the coronary artery and subclinical pericarditis assessed the presence and monitoring of therapy response by PET and CT scan.
Topics: Aged; Arteritis; Coronary Artery Disease; Female; Glucocorticoids; Humans; Immunoglobulin G; Pericar | 2018 |
Critical review of: Efficacy of immunoglobulin plus prednisone for prevention of coronary artery prednisolone for prevention of coronary abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial.
Topics: Anti-Inflammatory Agents; Coronary Artery Disease; Coronary Vessel Anomalies; Female; Humans; Immuno | 2013 |
Metal allergy to everolimus-eluting cobalt chromium stents confirmed by positive skin testing as a cause of recurrent multivessel in-stent restenosis.
Topics: Anti-Allergic Agents; Cardiovascular Agents; Chromium Alloys; Coronary Angiography; Coronary Artery | 2016 |
Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
Topics: Analysis of Variance; Child, Preschool; Coronary Artery Disease; Female; Humans; Immunoglobulins, In | 2009 |
On pump coronary surgical revascularization in a patient with chronic immune thrombocytopenic purpura.
Topics: Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery Disease; Female; Glucocorticoids; Hu | 2010 |
Giant tumorous lesions (correction of legions) surrounding the right coronary artery associated with immunoglobulin-G4-related systemic disease.
Topics: Aged; Angina Pectoris; Anti-Inflammatory Agents; Autoimmune Diseases; Coronary Aneurysm; Coronary An | 2011 |
Management of Kawasaki disease: corticosteroids revisited.
Topics: Anti-Inflammatory Agents; Coronary Artery Disease; Coronary Vessel Anomalies; Female; Humans; Immuno | 2012 |
Catheter-induced bilateral coronary ostium dissection in a patient with long-term steroid therapy.
Topics: Adult; Cardiac Catheters; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Dru | 2012 |